Search

Displaying results 3791 - 3800 of 9129 in total
  1. Drug

    Glutamic acid

    go.drugbank.com/drugs/DB00142
    ApprovedInvestigationalNutraceutical

    A peptide that is a homopolymer of glutamic acid.

    Mixtures: Aminosyn II 7% M In 10% Dextrose(dual Chamber), Aminosyn II 8.5% M In 20% Dextrose (dual Chamber)
  2. Drug

    Gadoteric acid

    go.drugbank.com/drugs/DB09132
    ApprovedInvestigational

    due to a decreased tendency of gadolinium dechelation. … Gadoteric acid, commonly used in the salt form gadoterate meglumine, is a macrocyclic, ionic gadolinium-based contrast agent (GBCA).

    Categories: Compounds used in a research, industrial, or household settingProducts: Dotagraf 0,5 mmol/ml Injektionslösung im Einzeldosisbehältnis, Dotavision 0,5 mmol/ml Injektionslösung im Einzeldosisbehältnis
  3. Drug

    Balanol

    go.drugbank.com/drugs/DB04098
    Experimental

    Categories: Cyclic AMP-Dependent Protein Kinases, antagonists & inhibitors
  4. Drug

    UK-432097

    go.drugbank.com/drugs/DB12691
    Investigational

    UK-432,097 has been used in trials studying the treatment of Pulmonary Disease, Chronic Obstructive.

    Categories: Adenosine A receptor agonists, Adenosine A2 Receptor Agonists
  5. Drug

    Bumetanide

    go.drugbank.com/drugs/DB00887
    ApprovedInvestigational

    Bumetanide is a sulfamyl diuretic.

    Categories: Increased Diuresis at Loop of Henle
  6. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

    Synonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
  7. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.

  8. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

  9. Drug

    Osemozotan

    go.drugbank.com/drugs/DB05339
    Experimental

    MN-305 is a novel, potent and highly selective serotonin 5-HT1A receptor agonist under development by MediciNova for the treatment of anxiety disorders beginning with Generalized Anxiety Disorder (GAD)

  10. Drug

    Tocilizumab

    go.drugbank.com/drugs/DB06273
    ApprovedInvestigational

    [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome. … [L44483] Tocilizumab-bavi, a biosimilar drug, was approved by the FDA in September 2023.[L48385].